AAO: Corneal Toxicity Reported With Mirvetuximab Soravtansine

TUESDAY, Oct. 22, 2024-- For patients receiving mirvetuximab soravtansine (MIRV) treatment for primary gynecologic malignancies, corneal toxicity is not uncommon, but usually resolves, according to a study presented at the annual meeting of the...